About this Journal Submit a Manuscript Table of Contents
Advances in Urology
Volume 2012 (2012), Article ID 421709, 8 pages
http://dx.doi.org/10.1155/2012/421709
Review Article

Surveillance and Treatment of Non-Muscle-Invasive Bladder Cancer in the USA

1Department of Urologic Surgery, Vanderbilt University, Nashville, TN 37203, USA
2Allergan Inc., P.O. Box 19534, Irvine, CA 92623, USA
3Xcenda, 4114 Woodlands Parkway Suite 500, Palm Harbor, FL 34685, USA

Received 2 December 2011; Accepted 22 February 2012

Academic Editor: Peter E. Clark

Copyright © 2012 Daniel A. Barocas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. Siegel, J. Xu, and E. Ward, “Cancer statistics, 2010,” CA Cancer Journal for Clinicians, vol. 60, no. 5, pp. 277–300, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. E. B. C. Avritscher, C. D. Cooksley, H. B. Grossman et al., “Clinical model of lifetime cost of treating bladder cancer and associated complications,” Urology, vol. 68, no. 3, pp. 549–553, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. J. A. Witjes and K. Hendricksen, “Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results,” European Urology, vol. 53, no. 1, pp. 45–52, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. C. L. Pashos, M. F. Botteman, B. L. Laskin, and A. Redaelli, “Bladder cancer: epidemiology, diagnosis, and management,” Cancer Practice, vol. 10, no. 6, pp. 311–322, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. M. P. Koya, M. A. Simon, and M. S. Soloway, “Complications of intravesical therapy for urothelial cancer of the bladder,” Journal of Urology, vol. 175, no. 6, pp. 2004–2010, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. K. L. Kilbridge and P. Kantoff, “Intravesical therapy for superficial bladder cancer: is it a wash?” Journal of Clinical Oncology, vol. 12, no. 1, pp. 1–4, 1994. View at Scopus
  7. A. M. Kamat and D. L. Lamm, “Intravesical therapy for bladder cancer,” Urology, vol. 55, no. 2, pp. 161–168, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. D. L. Lamm, B. A. Blumenstein, J. D. Crissman et al., “Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study,” Journal of Urology, vol. 163, no. 4, pp. 1124–1129, 2000. View at Scopus
  9. M. Colombel, F. Saint, D. Chopin, B. Malavaud, L. Nicolas, and P. Rischmann, “The effect of ofloxacin on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized prospective, double-blind, placebo controlled, multicenter study,” Journal of Urology, vol. 176, no. 3, pp. 935–939, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Schmidbauer and G. Lindenau, “Follow-up of nonmuscle invasive transitional cell carcinoma of the bladder: how and how often?” Current Opinion in Urology, vol. 18, no. 5, pp. 504–507, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Lamm, “Bladder cancer: improving care with better classification and risk stratification,” Journal of Urology, vol. 178, no. 4, pp. 1146–1147, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. B. W. G. van Rhijn, M. Burger, Y. Lotan et al., “Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy,” European Urology, vol. 56, no. 3, pp. 430–442, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. National Comprehensive Cancer Network, “Clinical Practice Guidelines in Oncology: Bladder Cancer,” Version 2, 2011.
  14. M. Babjuk, W. Oosterlinck, R. Sylvester, et al., “Guidelines on TaT1 (non-muscle invasive) bladder cancer,” European Association of Urology, 2011.
  15. R. Madeb, D. Golijanin, K. Noyes et al., “Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors,” Cancer, vol. 115, no. 12, pp. 2660–2670, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. M. C. Hall, S. S. Chang, G. Dalbagni et al., “Guideline for the management of nonmuscle invasive bladder cancer (Stages Ta, T1, and Tis): 2007 update,” Journal of Urology, vol. 178, no. 6, pp. 2314–2330, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. G. J. Huang, A. S. Hamilton, M. Lo, J. P. Stein, and D. F. Penson, “Predictors of intravesical therapy for nonmuscle invasive bladder cancer: results from the surveillance, epidemiology and end results program 2003 patterns of care project,” Journal of Urology, vol. 180, no. 2, pp. 520–524, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Chamie, C. S. Saigal, J. Lai et al., “Compliance with guidelines for patients with bladder cancer: variation in the delivery of care,” Cancer, vol. 117, no. 23, pp. 5392–5401, 2011. View at Publisher · View at Google Scholar
  19. H. B. Grossman, M. A. O’Donnell, M. S. Cookson, R. E. Greenberg, and T. E. Keane, “Bacillus Calmette-Guérin failures and beyond: contemporary management of non-muscle-invasive bladder cancer,” Reviews in Urology, vol. 10, no. 4, pp. 281–289, 2008.
  20. A. R. Metwalli and A. M. Kamat, “Controversial issues and optimal management of stage T1G3 bladder cancer,” Expert Review of Anticancer Therapy, vol. 6, no. 8, pp. 1283–1294, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Herr, B. Konety, J. Stein, C. N. Sternberg, and D. P. Wood, “Optimizing outcomes at every stage of bladder cancer: do we practice it?” Urologic Oncology: Seminars and Original Investigations, vol. 27, no. 1, pp. 72–74, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. B. L. Gallagher, F. N. Joudi, J. L. Maymí, and M. A. O'Donnell, “Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy,” Urology, vol. 71, no. 2, pp. 297–301, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Huncharek and B. Kupelnick, “Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: Metaanalytic reevaluation,” American Journal of Clinical Oncology, vol. 26, no. 4, pp. 402–407, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Weiss, O. J. Ott, M. Wittlinger et al., “Treatment options for high-risk T1 bladder cancer: status quo and future perspectives of radiochemotherapy,” Strahlentherapie und Onkologie, vol. 184, no. 9, pp. 443–449, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. M. F. Botteman, C. L. Pashos, A. Redaelli, B. Laskin, and R. Hauser, “The health economics of bladder cancer: a comprehensive review of the published literature,” PharmacoEconomics, vol. 21, no. 18, pp. 1315–1330, 2003. View at Scopus
  26. K. D. Sievert, B. Amend, U. Nagele et al., “Economic aspects of bladder cancer: what are the benefits and costs?” World Journal of Urology, vol. 27, no. 3, pp. 295–300, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Lee, D. Globe, D. Colayco, A. Gilmore, and T. Bramley, “Economic consequences of preventable bladder tumor recurrences in non-muscle invasive bladder cancer,” in Proceedings of the 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Baltimore, Md, USA, May 2011.
  28. OCEBM Levels of Evidence Working Group, “The Oxford 2011 Levels of Evidence,” Oxford Centre for Evidence-Based Medicine, http://www.cebm.net/index.aspx?o=5653.
  29. Z. Kirkali, T. Chan, M. Manoharan et al., “Bladder cancer: epidemiology, staging and grading, and diagnosis,” Urology, vol. 66, no. 6, pp. 4–34, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. D. J. Gallagher and M. I. Milowsky, “Bladder cancer,” Current Treatment Options in Oncology, vol. 10, no. 3-4, pp. 205–215, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. S. J. Dovedi and B. R. Davies, “Emerging targeted therapies for bladder cancer: a disease waiting for a drug,” Cancer and Metastasis Reviews, vol. 28, no. 3-4, pp. 355–367, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. P. E. Clark, “Bladder cancer,” Current Opinion in Oncology, vol. 19, no. 3, pp. 241–247, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. A. R. Zlotta, N. E. Fleshner, and M. A. Jewett, “The management of BCG failure in non-muscle-invasive bladder cancer: an update,” Journal of the Canadian Urological Association, vol. 3, no. 6, pp. S199–S205, 2009. View at Scopus
  34. D. A. Barocas and P. E. Clark, “Bladder cancer,” Current Opinion in Oncology, vol. 20, no. 3, pp. 307–314, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. S. M. Donat, “Evaluation and follow-up strategies for superficial bladder cancer,” Urologic Clinics of North America, vol. 30, no. 4, pp. 765–776, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. G. E. Amiel and S. P. Lerner, “Combining surgery and chemotherapy for invasive bladder cancer: current and future directions,” Expert Review of Anticancer Therapy, vol. 6, no. 2, pp. 281–291, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. E. S. Gwynn and P. E. Clark, “Bladder cancer,” Current Opinion in Oncology, vol. 18, no. 3, pp. 277–283, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. F. M. Martin and A. M. Kamat, “Definition and management of patients with bladder cancer who fail BCG therapy,” Expert Review of Anticancer Therapy, vol. 9, no. 6, pp. 815–820, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. B. H. Bochner, “Optimal timing of radical cystectomy for patients with T1 bladder cancer,” Urologic Oncology: Seminars and Original Investigations, vol. 27, no. 3, pp. 329–331, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. J. J. Patard, A. Rodriguez, and B. Lobel, “The current status of intravesical therapy for superficial bladder cancer,” Current Opinion in Urology, vol. 13, no. 5, pp. 357–362, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. M. C. Smaldone, B. A. Gayed, J. J. Tomaszewski, and J. R. Gingrich, “Strategies to enhance the efficacy of intravescical therapy for non-muscle invasive bladder cancer,” Minerva Urologica e Nefrologica, vol. 61, no. 2, pp. 71–89, 2009. View at Scopus
  42. M. C. Smaldone, D. P. Casella, D. R. Welchons, and J. R. Gingrich, “Investigational therapies for non-muscle invasive bladder cancer,” Expert Opinion on Investigational Drugs, vol. 19, no. 3, pp. 371–383, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. A. M. Nieder, M. Brausi, D. Lamm et al., “Management of stage T1 tumors of the bladder: International Consensus Panel,” Urology, vol. 66, no. 6, pp. 108–125, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Böhle, D. Jocham, and P. R. Bock, “Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity,” Journal of Urology, vol. 169, no. 1, pp. 90–95, 2003. View at Scopus
  45. R. J. Sylvester, W. Oosterlinck, and A. P. M. Van Der Meijden, “A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials,” Journal of Urology, vol. 171, no. 6, pp. 2186–2190, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Hendricksen and J. A. Witjes, “Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer,” Current Opinion in Urology, vol. 17, no. 5, pp. 352–357, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. N. Howlader, A. M. Noone, M. Krapcho, et al., “SEER Cancer Statistics Review, 1975–2008,” National Cancer Institute, Bethesda, Md, USA, 2011, http://seer.cancer.gov/csr/1975_2008/.
  48. K. F. Brookfield, M. C. Cheung, C. Gomez et al., “Survival disparities among African American women with invasive bladder cancer in Florida,” Cancer, vol. 115, no. 18, pp. 4196–4209, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. L. S. Borden, P. E. Clark, and M. C. Hall, “Bladder cancer,” Current Opinion in Oncology, vol. 17, no. 3, pp. 275–280, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Ploeg, K. K. H. Aben, and L. A. Kiemeney, “The present and future burden of urinary bladder cancer in the world,” World Journal of Urology, vol. 27, no. 3, pp. 289–293, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. R. J. Sylvester, A. P. M. Van Der Meijden, W. Oosterlinck et al., “Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials,” European Urology, vol. 49, no. 3, pp. 466–475, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Haukaas, L. DÆhlin, H. Maartmann-Moe, and N. M. Ulvik, “The long-term outcome in patients with superficial transitional cell carcinoma of the bladder: a single-institutional experience,” BJU International, vol. 83, no. 9, pp. 957–963, 1999. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Wade and J. D. Seigne, “Surgical management of bladder cancer in 2003,” Expert Review of Anticancer Therapy, vol. 3, no. 6, pp. 781–792, 2003. View at Scopus
  54. H. W. Herr, “Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome,” Journal of Urology, vol. 163, no. 1, pp. 60–62, 2000. View at Scopus
  55. M. S. Cookson, H. W. Herr, Z. F. Zhang, S. Soloway, P. C. Sogani, and W. R. Fair, “The treated natural history of high risk superficial bladder cancer: 15-year outcome,” Journal of Urology, vol. 158, no. 1, pp. 62–67, 1997. View at Publisher · View at Google Scholar · View at Scopus
  56. S. Holmang, H. Hedelin, C. Anderstrom, S. L. Johansson, and M. S. Soloway, “The relationship among multiple recurrences, progression and prognosis of patients with stages TA and T1 transitional cell cancer of the bladder followed for at least 20 years,” Journal of Urology, vol. 153, no. 6, pp. 1823–1827, 1995. View at Scopus
  57. D. Lamm, M. Colombel, R. Persad et al., “Clinical practice recommendations for the management of non-muscle invasive bladder cancer,” European Urology, Supplements, vol. 7, no. 10, pp. 651–666, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. E. Solsona, I. Iborra, J. V. Ricós, J. L. Monrós, J. Casanova, and R. Dumont, “Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup,” Journal of Urology, vol. 161, no. 4, pp. 1120–1123, 1999. View at Publisher · View at Google Scholar · View at Scopus
  59. D. A. Tolley, M. K. B. Parmar, K. M. Grigor et al., “The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of followup,” Journal of Urology, vol. 155, no. 4, pp. 1233–1238, 1996. View at Publisher · View at Google Scholar · View at Scopus
  60. R. J. Sylvester, W. Oosterlinck, and J. A. Witjes, “The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials,” European Urology, vol. 53, no. 4, pp. 709–719, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. H. H. Kim and C. lee, “Intravesical mitomycin C instillation as a prophylactic treatment of superficial bladder tumor,” Journal of Urology, vol. 141, no. 6, pp. 1337–1340, 1989. View at Scopus
  62. J. Kalsi, S. J. Harland, and M. R. Feneley, “Electromotive drug administration with mitomycin C for intravesical treatment of non-muscle invasive transitional cell carcinoma,” Expert Opinion on Drug Delivery, vol. 5, no. 1, pp. 137–145, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. S. M. Di Stasi, A. Giannantoni, R. L. Stephen et al., “Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study,” Journal of Urology, vol. 170, no. 3, pp. 777–782, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. P. U. Malmström, R. J. Sylvester, D. E. Crawford et al., “An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus Bacillus Calmette-Guérin for non-muscle-invasive bladder cancer,” European Urology, vol. 56, no. 2, pp. 247–256, 2009. View at Publisher · View at Google Scholar · View at Scopus
  65. R. J. Sylvester, A. P. M. Van der Meijden, and D. L. Lamm, “Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials,” Journal of Urology, vol. 168, no. 5, pp. 1964–1970, 2002. View at Scopus
  66. S. S. Chang and M. S. Cookson, “Radical cystectomy for bladder cancer: the case for early intervention,” Urologic Clinics of North America, vol. 32, no. 2, pp. 147–155, 2005. View at Publisher · View at Google Scholar · View at Scopus
  67. A. P. M. Van der Meijden, R. J. Sylvester, W. Oosterlinck, W. Hoeltl, and A. V. Bono, “Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European organisation for research and treatment of cancer genito-urinary group phase III trial,” European Urology, vol. 44, no. 4, pp. 429–434, 2003. View at Publisher · View at Google Scholar · View at Scopus
  68. J. P. Stein, G. Lieskovsky, R. Cote et al., “Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients,” Journal of Clinical Oncology, vol. 19, no. 3, pp. 666–675, 2001. View at Scopus
  69. F. N. Joudi and M. A. O'Donnell, “Second-line intravesical therapy versus cystectomy for bacille Calmette-Gué (BCG) failures,” Current Opinion in Urology, vol. 14, no. 5, pp. 271–275, 2004. View at Publisher · View at Google Scholar · View at Scopus
  70. A. Shabsigh, R. Korets, K. C. Vora et al., “Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology,” European Urology, vol. 55, no. 1, pp. 164–176, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. A. G. van der Heijden, P. M. J. Moonen, E. B. Cornel et al., “Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response,” Journal of Urology, vol. 176, no. 4, pp. 1349–1353, 2006. View at Publisher · View at Google Scholar · View at Scopus
  72. M. Maffezzini, F. Campodonico, G. Canepa, G. Capponi, and V. Fontana, “Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1-G2, low- or intermediate risk, transitional cell carcinoma of the bladder,” European Urology, vol. 51, no. 4, pp. 956–961, 2007. View at Publisher · View at Google Scholar · View at Scopus
  73. M. A. Laudano, L. J. Barlow, A. M. Murphy et al., “Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy,” Urology, vol. 75, no. 1, pp. 134–137, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. C. Lee, S. Gruschkus, D. Colayco, T. Bramley, and D. Globe, “Treatment patterns and costs of treating non-muscle invasive bladder cancer (NMIBC),” in Proceedings of the 12th Annual Meeting of the Society of Urologic Oncology, Rockville, Md, USA, November-December 2011.
  75. K. Chamie, C. S. Saigal, J. Lai et al., “Quality of care in patients with bladder cancer: the need to improve care beyond a case report,” in Proceedings of the American Urological Association Annual Meeting, Washington, DC, USA, May 2011.
  76. A. B. Mariotto, K. Robin Yabroff, Y. Shao, E. J. Feuer, and M. L. Brown, “Projections of the cost of cancer care in the united states: 2010–2020,” Journal of the National Cancer Institute, vol. 103, no. 2, pp. 117–128, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. Y. Lotan, A. M. Kamat, M. P. Porter et al., “Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology,” Cancer, vol. 115, no. 18, pp. 4096–4103, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. B. B. Reeve, A. L. Potosky, A. W. Smith et al., “Impact of cancer on health-related quality of life of older americans,” Journal of the National Cancer Institute, vol. 101, no. 12, pp. 860–868, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. D. Williams-Cox, “A mixed-method study into quality of life for bladder cancer patients,” Professional Nurse, vol. 19, no. 6, pp. 343–347, 2004. View at Scopus
  80. M. F. Botteman, C. L. Pashos, R. S. Hauser, B. L. Laskin, and A. Redaelli, “Quality of life aspects of bladder cancer: a review of the literature,” Quality of Life Research, vol. 12, no. 6, pp. 675–688, 2003. View at Publisher · View at Google Scholar · View at Scopus
  81. J. P. Parkinson and B. R. Konety, “Health related quality of life assessments for patients with bladder cancer,” Journal of Urology, vol. 172, no. 6, pp. 2130–2136, 2004. View at Publisher · View at Google Scholar · View at Scopus
  82. K. Yoshimura, N. Utsunomiya, K. Ichioka, Y. Matsui, A. Terai, and Y. Arai, “Impact of superficial bladder cancer and transurethral resection on general health-related quality of life: an SF-36 survey,” Urology, vol. 65, no. 2, pp. 290–294, 2005. View at Publisher · View at Google Scholar · View at Scopus
  83. A. Böhle, F. Balck, J. Von Wietersheim, and D. Jocham, “The quality of life during intravesical bacillus Calmette-Guerin therapy,” Journal of Urology, vol. 155, no. 4, pp. 1221–1226, 1996. View at Publisher · View at Google Scholar · View at Scopus
  84. D. Mack and J. Frick, “Quality of life in patients undergoing bacille Calmette-Guérin therapy for superficial bladder cancer,” British Journal of Urology, vol. 78, no. 3, pp. 369–371, 1996. View at Scopus
  85. G. S. Kulkarni, S. M. H. Alibhai, A. Finelli et al., “Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer,” Cancer, vol. 115, no. 23, pp. 5450–5459, 2009. View at Publisher · View at Google Scholar · View at Scopus
  86. D. Barocas, D. Globe, D. Colayco, A. Gilmore, and T. Bramley, “Humanistic consequences of preventable bladder tumor recurrences in non-muscle invasive bladder cancer,” in Proceedings of the 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Baltimore, Md, USA, May 2011.